Andy Billinton PhD appointed as Chief Scientific Officer Expansion into larger facilities at the Babraham Research Campus Cambridge, 23rd June 2022: Transine Therapeutics today announced
Dr Alison Strutt joins Kynos senior management team as CFO Brings extensive strategic, transactional, and operational experience in biotech and large pharma to the Kynos
WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the
Company adds £4.6m additional seed funding Strengthens investor syndicate with Epidarex joining as a new investor Enhances ability to leverage unique SINEUP® platform and rapidly
Curve’s innovative mammalian cell drug discovery platform to enable identification and optimisation of novel small molecule drug candidates against MSD targets Potentially game-changing platform enables
The first targeted C3 therapy approved in the EU Approval based on results from head-to-head PEGASUS Phase 3 study where Aspaveli demonstrated superiority to eculizumab
Leucid will work with Lonza on the Cocoon® Platform for Leucid Bio’s Phase I/II clinical studies with its lead candidate, LEU-011, for the treatment of
-Study of lead candidate to provide important information on safety, pharmacokinetics and pharmacodynamics to inform further clinical development in chronic inflammatory diseases–Highlights continued progress advancing
Epidarex-built start-up signs major global development partnership within 18 months of launch. Epidarex portfolio company will receive $24 million in an upfront payment and equity
London, UK – 21 October 2021 – Leucid Bio (“Leucid” or the “Company”), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, today announces